
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health is poised for success as its Revita and Rejuva candidates show promise in addressing the root causes of metabolic diseases and its innovative RAPID coverage pathway can speed up the regulatory-reimbursement process. Additionally, the correlation between Revita treatment and weight maintenance and potential for FDA approval and CMS reclassification highlights its potential for growth and success. However, like any clinical stage company, Fractyl Health does face risks in financing, reimbursement, and regulatory challenges that should be carefully monitored.
Bears say
Fractyl Health is facing significant challenges with its Revita and Rejuva candidates as they target root causes of metabolic diseases such as obesity and type 2 diabetes. While positive feedback from the FDA regarding the De Novo filing pathway has been received, uncertainties remain surrounding the safety and efficacy of the candidates, making it difficult to predict their success in the market. Additionally, data from past clinical trials suggest that weight regain is a common issue after discontinuation of similar treatments, raising concerns about the potential durability of Fractyl's products and their long-term impact on patients.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares